Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220460 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder
A Phase 2 study of Bipolar I or II Disorder, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT07220460: Recruiting Phase 2 study of Bipolar I or II Disorder, sponsored by AbbVie.
NCT07220460 is a Phase 2 study of Bipolar I or II Disorder that is actively recruiting participants, run by AbbVie. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220460, a Phase 2 study of Bipolar I or II Disorder, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an investigational drug being developed for the treatment of depressive episodes in adult participants with bipolar I or II disorder. Participants with bipolar I or II disorder who are currently experiencing a depressive episode will enter the study and be treated with open-label ABBV-932. Approximately 200 adult participants with bipolar I or II disorder will be enrolled in approximately 50 sites in the United States and Puerto Rico. Participants will receive oral capsules of ABBV-932 for a 26-week treatment period. The treatment period will be followed by a safety follow-up (SFU) period of 30 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regularly scheduled visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Primary Outcome
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG ABBV-932
Study Locations (20)
California
- Advanced Research Center /ID# 273474 - Anaheim
- Axiom Research /ID# 273482 - Colton
- Collaborative Neuroscience Research - Garden Grove /ID# 273492 - Garden Grove
- Sun Valley Research Center /ID# 273472 - Imperial
- Synergy San Diego /ID# 278340 - Lemon Grove
- Alliance for Research Alliance for Wellness /ID# 273477 - Long Beach
- Nrc Research Institute - Los Angeles /ID# 278450 - Los Angeles
- Excell Research /ID# 273483 - Oceanside
- Inland Psychiatric Medical Group Inc. /ID# 273471 - Temecula
- Sunwise Clinical Research /ID# 278165 - Walnut Creek
Florida
- Cns Healthcare - Jacksonville /ID# 278332 - Jacksonville
- GMI Florida - Central Miami Medical Institute /ID# 273486 - Miami
- Allied Biomedical Res Inst Inc /ID# 273476 - Miami
- Floridian Clinical Research - Miami Lakes /ID# 279379 - Miami Lakes
- K2 Medical Research - Orlando - South Orlando Avenue /ID# 273487 - Orlando
- Apg Research /ID# 278439 - Orlando
- Segal Trials - West Broward Outpatient Research Site /ID# 273496 - Tamarac
- Health Synergy Clinical Research /ID# 279384 - West Palm Beach
Arizona
- Ima Clinical Research Phoenix (Alea) /ID# 278047 - Phoenix
Connecticut
- Connecticut Clinical Research - Cromwell /ID# 278116 - Cromwell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT07220460 shows while recruiting
NCT07220460 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Bipolar I or II Disorder appearing as the primary indexed condition, and to 1 intervention - of which ABBV-932 is the first listed.
NCT07220460 names 20 study sites across 4 states, led by California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT07220460 about?
NCT07220460 is a clinical study titled "Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder". Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is to assess how safe and effective ABBV-932 is in treating participants with depressive episodes associated with bipolar I or II disorder. ABBV-932 is an...
What is the current status of trial NCT07220460?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2025-09-30. Estimated completion is 2027-04.
What conditions does trial NCT07220460 study?
This clinical trial studies the following conditions: Bipolar I or II Disorder.
What interventions are being tested in trial NCT07220460?
The interventions under investigation include: ABBV-932 (DRUG).
Who is sponsoring clinical trial NCT07220460?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07220460 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07220460's enrollment target sits among peer trials
200 304th of 2000 higher than 1,653 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI